Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 90% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. The Company has the unique ability to link these variants to gene function and precisely map disease pathways. Nucleome’s cell type-specific platform creates high resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types, enabling the discovery and development of novel, better and safer drugs. The initial focus of the company is on lymphocytes and related autoimmune disease. Nucleome’s ambition is to build a robust pipeline of drug assets, with corresponding biomarkers. Nucleome Therapeutics was founded by leading experts in gene regulation from the University of Oxford. For more information, please visit www.nucleome.com.
External link for Nucleome Therapeutics
Oxford, GB
Nucleome Therapeutics reposted this
Our Drug Discovery Team are looking for a talented scientist with a background in cellular & molecular immune cell biology for a 12-month maternity cover contract. The role will support the experimental progression of drug targets generated by Nucleome’s proprietary technology platform. https://lnkd.in/eXfR2kUy #hiring #biotech #careers
Our Drug Discovery Team are looking for a talented scientist with a background in cellular & molecular immune cell biology for a 12-month maternity cover contract. The role will support the experimental progression of drug targets generated by Nucleome’s proprietary technology platform. https://lnkd.in/eXfR2kUy #hiring #biotech #careers
We are very pleased to announce the appointment of Dr Mark Bodmer as CEO of Nucleome. https://lnkd.in/ebXAVgJF Commenting Chair Dr Russell Grieg said: “Our pioneering science and technology are the innovative foundation for the future of Nucleome. In addition to Mark’s R&D background resulting in many marketed medicines, he has broad experience in company-building, business development, financing and M&A. His unusual combination of R&D and commercial expertise in driving great science towards patient benefits will be crucial in delivering Nucleome’s continued development.” #CEO #hiring #biotech #genomics
Nucleome Therapeutics reposted this
Mark Bodmer takes top job at Nucleome Therapeutics reda the article: https://lnkd.in/e2a7WqXB
Welcome to Dr Mark Bodmer as CEO of Nucleome Therapeutics. https://lnkd.in/ebXAVgJF. Commenting, Mark said: “Nucleome has built a revolutionary technology platform which moves the field of genetics in medicine from its 1-Dimensional linear code to the interactions within its 3-Dimensional structure. This allows us to determine the regulatory wiring of gene function in health and disease in unprecedented detail. Variants in non-coding regions of the genome can be mapped to the genes they control, which are often far away in 1-D but are next-door neighbours in 3-D. Nucleome’s uniquely powerful technology fills a critical gap in the application of genetics to drug discovery and healthcare. The vast majority of genome sequence variants lie outside of protein-coding regions. Yet they play a critical role in shaping biological function and disease. Nucleome’s capability to bridge these sequence variants to biology brings genomics into an entirely new era of the application of genetics to drug target discovery and precision medicine. It is a privilege to be given the opportunity to lead this ground-breaking company into its next phase of growth.” #CEO #hiring #biotech #genomics
We are excited to celebrate our most recent promotions within the team! It is rewarding to see our team members develop and grow at Nucleome! Congratulations to Andrew Morris – Senior Manager, Digital Operations, Anna James-Bott – Senior Bioinformatician, and Brigid Davidson – Senior Research Assistant, on their new roles! #Promotions #Teamwork #Biotech #DarkGenome #Genomics
Our CEO and Founder, Danuta Jeziorska, has been featured by Oxford University Innovation in their latest article concerning increasing diversity and gender parity in entrepreneurship. Danuta shared her insights on the cultural redefinition of leadership and the importance of highlighting the unique strengths of female leaders. Her journey, supported by various Oxford initiatives, exemplifies the transformative impact of empowering women in entrepreneurship. While progress has been made, there's still much work to be done. We applaud the efforts of all organizations and individuals working towards a more equitable future in entrepreneurship. #DiversityInEntrepreneurship #WomenInBusiness #Innovation
Oxford University Innovation backs the #InternationalWomensDay2024 call for accelerating women’s equality through creation of gender parity in enterprise. We've scoped a five-point plan to increase the proportion of women founders to 34% by 2025. Mairi Gibbs, Chief Operating Officer of OUI, said: "According to the consultancy Beauhurst, less than 8 per cent of UK university spinouts had all-women founding teams in 2023, while over 75 per cent were all-male. That’s a significant improvement on 2016 when all-women founded spinouts represented an alarming zero per cent, but if progress continues at this pace, it will take half a century to bridge the gap. That is why we are calling for a plan to deliver our ambition to reach 34 per cent by 2025." Read more ⬇ https://lnkd.in/eycQ-ybx #femalefounders #womenfounders #innovation #technology #startups #spinouts #entrepeneurship University of Oxford | EnSpire Oxford | Enterprising Women Oxford | Department for Science, Innovation and Technology | Advanced Oxford | Harwell Science and Innovation Campus | University of Oxford, Begbroke Science Park | The Oxford Science Park (TOSP) | Social Sciences Division, University of Oxford | TORCH | The Oxford Research Centre in the Humanities | Molly Stevens | Danuta Jeziorska | Holly Reeve
Passionate about promoting inclusivity of diverse leadership styles, our CEO and Founder, Dr Danuta Jeziorska, highlights how we can help empower female leaders in business: "We need to embrace vulnerability, empathy, and compassion as pillars of strength. By reshaping the narrative of what it means to be a leader, we will promote inclusivity of diverse leadership styles." We at Nucleome, reaffirm our commitment to fostering an environment where women are able to thrive, excel and lead. We recognise the importance of diversity in driving innovation and are proud to champion the advancement of women. Happy International Women’s Day! #iwd2024
This International Women’s Day, Danuta Jeziorska, CEO and Co-founder of Nucleome Therapeutics, details how we can help empower female leaders in business 👇 #IWD2024 #FemaleFounders #Innovation #Entrepeneurship University of Oxford | EnSpire Oxford | Oxford University Innovation
Our CEO and Founder, Danuta Jeziorska, is featured in the latest instalment of Citeline Commercial's #ScripAsks series by Eleanor Malone. In this insightful discussion with fellow biopharma leaders, Danuta talks about the transformative technologies poised to shape 2024. She outlines her predictions for a groundbreaking "revolutionary leap into the dark genome," with potential to reshape the landscape of drug discovery. 👉 You can read the article here: https://lnkd.in/dWeM2Bcy #2024Predictions #DarkGenome #Genomics #PrecisionMedicine #DrugDiscovery
Our CEO and Scientific Founder Danuta Jeziorska recently discussed the vital aspects of team building at the early stages of ventures with CEOs from pre-seed and seed stage companies across Europe as part of the LifeScience ORG NEXTGen series. Many thanks to LifeScience ORG for organising this event!
nextGEN INSIGHTS / The CEO: Danuta Jeziorska (CEO & Academic Founder Nucleome Therapeutics) - The first 15 hires. Wed, 31st Jan @ 4pm GMT / 5pm CET Join the conversation: members.lifescienceorg.com nextGEN is a community for Pre-Seed / Seed-stage founders of life science ventures to connect - share - learn This meeting is open to members of LifeScience ORG - apply for membership here: www.lifescienceorg.com #nextgen #lifescience #biotechnology #biotech #medtech #digitalhealth
This content isn’t available here
Access this content and more in the LinkedIn app